Cargando…

Targeting aggressive osteosarcoma with a peptidase-enhanced cytotoxic melphalan flufenamide

BACKGROUND: Low survival rates in metastatic high-grade osteosarcoma (HGOS) have remained stagnant for the last three decades. This study aims to investigate the role of aminopeptidase N (ANPEP) in HGOS progression and its targeting with a novel lipophilic peptidase-enhanced cytotoxic compound melph...

Descripción completa

Detalles Bibliográficos
Autores principales:	Byrgazov, Konstantin, Anderson, Claes, Salzer, Benjamin, Bozsaky, Eva, Larsson, Rolf, Gullbo, Joachim, Lehner, Manfred, Lehmann, Fredrik, Slipicevic, Ana, Kager, Leo, Fryknäs, Mårten, Taschner-Mandl, Sabine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7391428/ https://www.ncbi.nlm.nih.gov/pubmed/32774473 http://dx.doi.org/10.1177/1758835920937891

Ejemplares similares

Melphalan flufenamide inhibits osteoclastogenesis by suppressing proliferation of monocytes
por: Byrgazov, Konstantin, et al.
Publicado: (2021)

The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA.
por: Olivier, Timothée, et al.
Publicado: (2022)

Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma
por: Morabito, Fortunato, et al.
Publicado: (2021)

Authors’ reply: Perspective: The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA
por: Schjesvold, Fredrik H, et al.
Publicado: (2022)

Effects of hypoxia on human cancer cell line chemosensitivity
por: Strese, Sara, et al.
Publicado: (2013)

Novel Peptide-drug Conjugate Melflufen Efficiently Eradicates Bortezomib-resistant Multiple Myeloma Cells Including Tumor-initiating Myeloma Progenitor Cells
por: Byrgazov, Konstantin, et al.
Publicado: (2021)

Melflufen - a peptidase-potentiated alkylating agent in clinical trials
por: Wickström, Malin, et al.
Publicado: (2017)

Ex Vivo Activity of Cardiac Glycosides in Acute Leukaemia
por: Hallböök, Helene, et al.
Publicado: (2011)

A novel tumor spheroid model identifies selective enhancement of radiation by an inhibitor of oxidative phosphorylation
por: Karlsson, Henning, et al.
Publicado: (2019)

Screening for phenotype selective activity in multidrug resistant cells identifies a novel tubulin active agent insensitive to common forms of cancer drug resistance
por: Fryknäs, Mårten, et al.
Publicado: (2013)

Mechanistic characterization of a copper containing thiosemicarbazone with potent antitumor activity
por: Karlsson, Henning, et al.
Publicado: (2017)

In vitro and in vivo anti-leukemic activity of the peptidase-potentiated alkylator melflufen in acute myeloid leukemia
por: Strese, Sara, et al.
Publicado: (2016)

Single-cell transcriptional pharmacodynamics of trifluridine in a tumor-immune model
por: Selvin, Tove, et al.
Publicado: (2022)

Assessment in vitro of interactions between anti-cancer drugs and noncancer drugs commonly used by cancer patients
por: Andersson, Claes R., et al.
Publicado: (2022)

A Preclinical Embryonic Zebrafish Xenograft Model to Investigate CAR T Cells in Vivo
por: Pascoal, Susana, et al.
Publicado: (2020)

Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer
por: Nygren, Peter, et al.
Publicado: (2013)

Drug screen in patient cells suggests quinacrine to be repositioned for treatment of acute myeloid leukemia
por: Eriksson, A, et al.
Publicado: (2015)

Phenotypic screening platform identifies statins as enhancers of immune cell-induced cancer cell death
por: Selvin, Tove, et al.
Publicado: (2023)

Identification of molecular mechanisms for cellular drug resistance by combining drug activity and gene expression profiles
por: Rickardson, L, et al.
Publicado: (2005)

Iron chelators target both proliferating and quiescent cancer cells
por: Fryknäs, Mårten, et al.
Publicado: (2016)

Selective radiosensitization by nitazoxanide of quiescent clonogenic colon cancer tumour cells
por: Karlsson, Henning, et al.
Publicado: (2022)

Advances in the management of osteosarcoma
por: Bielack, Stefan S., et al.
Publicado: (2016)

Review of mifamurtide in the treatment of patients with osteosarcoma
por: Kager, Leo, et al.
Publicado: (2010)

Decreased melphalan accumulation in a human breast cancer cell line selected for resistance to melphalan.
por: Moscow, J. A., et al.
Publicado: (1993)

Mebendazole stimulates CD14+ myeloid cells to enhance T-cell activation and tumour cell killing
por: Rubin, Jenny, et al.
Publicado: (2018)

Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment
por: Lee, Se Ryeon, et al.
Publicado: (2019)

Multidrug resistance protein-mediated transport of chlorambucil and melphalan conjugated to glutathione.
por: Barnouin, K., et al.
Publicado: (1998)

Mutational spectrum of ATRX aberrations in neuroblastoma and associated patient and tumor characteristics
por: van Gerven, Michael R., et al.
Publicado: (2022)

Factors influencing the chemosensitization of melphalan by misonidazole.
por: Randhawa, V. S., et al.
Publicado: (1985)

Gastrointestinal Bleeding Secondary to High-Dose Melphalan Pretreatment in Patients with Multiple Myeloma Was Associated with the Mode of Melphalan Administration
por: Ge, Qunfang, et al.
Publicado: (2022)

Identification of a Novel Topoisomerase Inhibitor Effective in Cells Overexpressing Drug Efflux Transporters
por: Fayad, Walid, et al.
Publicado: (2009)

Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1B inhibition
por: Blom, Kristin, et al.
Publicado: (2019)

Sorafenib and nitazoxanide disrupt mitochondrial function and inhibit regrowth capacity in three-dimensional models of hepatocellular and colorectal carcinoma
por: Ek, Frida, et al.
Publicado: (2022)

Upregulation of CENPF is linked to aggressive features of osteosarcoma
por: Zou, Ping-An, et al.
Publicado: (2021)

Retracted: Gastrointestinal Bleeding Secondary to High-Dose Melphalan Pretreatment in Patients with Multiple Myeloma Was Associated with the Mode of Melphalan Administration
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023)

The effect of systemic hyperthermia on melphalan pharmacokinetics in mice.
por: Honess, D. J., et al.
Publicado: (1985)

The effect of radiosensitizers on the pharmacokinetics of melphalan and cyclophosphamide in the mouse.
por: Hinchliffe, M., et al.
Publicado: (1983)

Oral Melphalan Therapy in Advanced Malignant Disease
por: Clifford, Peter, et al.
Publicado: (1963)

Nitric oxide enhancement of melphalan-induced cytotoxicity.
por: Cook, J. A., et al.
Publicado: (1997)

Intravitreal and Subconjunctival Melphalan for Retinoblastoma in Transgenic Mice
por: Shah, Nisha V., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_0pectqsueabt4im8e8pnha7imh